CATALDO, MARIA LETIZIA
CATALDO, MARIA LETIZIA
Clinical and Translational Oncology
Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer
2021-01-01 De Angelis, C.; Fu, X.; Cataldo, M. L.; Nardone, A.; Pereira, R.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Sethunath, V.; Wang, T.; Hilsenbeck, S. G.; Benelli, M.; Migliaccio, I.; Guarducci, C.; Malorni, L.; Litchfield, L. M.; Liu, J.; Donaldson, J.; Selenica, P.; Brown, D. N.; Weigelt, B.; Reis-Filho, J. S.; Park, B. H.; Hurvitz, S. A.; Slamon, D. J.; Rimawi, M. F.; Jansen, V. M.; Jeselsohn, R.; Osborne, C. K.; Schiff, R.
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy
2020-01-01 De Angelis, Carmine; Nagi, Chandandeep; Hoyt, Cliff C; Liu, Linying; Roman, Kristin; Wang, Chichung; Zheng, Yi; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Nuciforo, Paolo; Wang, Tao; Tsimelzon, Anna; Mao, Sufeng; Hilsenbeck, Susan G; Trivedi, Meghana V; Cataldo, Maria Letizia; Pavlick, Anne; Wolff, Antonio C; Weigelt, Britta; Reis-Filho, Jorge S; Prat, Aleix; Gutierrez, Carolina; Osborne, Charles Kent; Rimawi, Mothaffar F; Schiff, Rachel
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
2019-01-01 Fu, X.; Pereira, R.; De Angelis, C.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Cataldo, M. L.; Sethunath, V.; Mehravaran, S.; Gutierrez, C.; Chamness, G. C.; Feng, Q.; O'Malley, B. W.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Cohen, O.; Wagle, N.; Nardone, A.; Jeselsohn, R.; Brown, M.; Rimawi, M. F.; Osborne, C. K.; Schiff, R.
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer
2023-01-01 Fu, Xiaoyong; Pereira, Resel; Liu, Chia-Chia; De Angelis, Carmine; Shea, Martin J; Nanda, Sarmistha; Qin, Lanfang; Mitchell, Tamika; Cataldo, Maria L; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Giuliano, Mario; Gutierrez, Carolina; Győrffy, Balázs; Trivedi, Meghana V; Cohen, Ofir; Wagle, Nikhil; Nardone, Agostina; Jeselsohn, Rinath; Rimawi, Mothaffar F; Osborne, C Kent; Schiff, Rachel
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer
2022-01-01 Bhat, R.; Thangavel, H.; Abdulkareem, N. M.; Vasaikar, S.; De Angelis, C.; Bae, L.; Cataldo, M. L.; Nanda, S.; Fu, X.; Zhang, B.; Schiff, R.; Trivedi, M. V.
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
2023-01-01 Cataldo, Maria Letizia; De Placido, Pietro; Esposito, Daniela; Formisano, Luigi; Arpino, Grazia; Giuliano, Mario; Bianco, Roberto; De Angelis, Carmine; Veneziani, Bianca Maria
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
2019-01-01 Nardone, A.; Weir, H.; Delpuech, O.; Brown, H.; De Angelis, C.; Cataldo, M. L.; Fu, X.; Shea, M. J.; Mitchell, T.; Veeraraghavan, J.; Nagi, C.; Pilling, M.; Rimawi, M. F.; Trivedi, M.; Hilsenbeck, S. G.; Chamness, G. C.; Jeselsohn, R.; Osborne, C. K.; Schiff, R.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer | 1-gen-2021 | De Angelis, C.; Fu, X.; Cataldo, M. L.; Nardone, A.; Pereira, R.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Sethunath, V.; Wang, T.; Hilsenbeck, S. G.; Benelli, M.; Migliaccio, I.; Guarducci, C.; Malorni, L.; Litchfield, L. M.; Liu, J.; Donaldson, J.; Selenica, P.; Brown, D. N.; Weigelt, B.; Reis-Filho, J. S.; Park, B. H.; Hurvitz, S. A.; Slamon, D. J.; Rimawi, M. F.; Jansen, V. M.; Jeselsohn, R.; Osborne, C. K.; Schiff, R. | |
| Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy | 1-gen-2020 | De Angelis, Carmine; Nagi, Chandandeep; Hoyt, Cliff C; Liu, Linying; Roman, Kristin; Wang, Chichung; Zheng, Yi; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Nuciforo, Paolo; Wang, Tao; Tsimelzon, Anna; Mao, Sufeng; Hilsenbeck, Susan G; Trivedi, Meghana V; Cataldo, Maria Letizia; Pavlick, Anne; Wolff, Antonio C; Weigelt, Britta; Reis-Filho, Jorge S; Prat, Aleix; Gutierrez, Carolina; Osborne, Charles Kent; Rimawi, Mothaffar F; Schiff, Rachel | |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer | 1-gen-2019 | Fu, X.; Pereira, R.; De Angelis, C.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Cataldo, M. L.; Sethunath, V.; Mehravaran, S.; Gutierrez, C.; Chamness, G. C.; Feng, Q.; O'Malley, B. W.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Cohen, O.; Wagle, N.; Nardone, A.; Jeselsohn, R.; Brown, M.; Rimawi, M. F.; Osborne, C. K.; Schiff, R. | |
| High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer | 1-gen-2023 | Fu, Xiaoyong; Pereira, Resel; Liu, Chia-Chia; De Angelis, Carmine; Shea, Martin J; Nanda, Sarmistha; Qin, Lanfang; Mitchell, Tamika; Cataldo, Maria L; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Giuliano, Mario; Gutierrez, Carolina; Győrffy, Balázs; Trivedi, Meghana V; Cohen, Ofir; Wagle, Nikhil; Nardone, Agostina; Jeselsohn, Rinath; Rimawi, Mothaffar F; Osborne, C Kent; Schiff, Rachel | |
| NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer | 1-gen-2022 | Bhat, R.; Thangavel, H.; Abdulkareem, N. M.; Vasaikar, S.; De Angelis, C.; Bae, L.; Cataldo, M. L.; Nanda, S.; Fu, X.; Zhang, B.; Schiff, R.; Trivedi, M. V. | |
| The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer | 1-gen-2023 | Cataldo, Maria Letizia; De Placido, Pietro; Esposito, Daniela; Formisano, Luigi; Arpino, Grazia; Giuliano, Mario; Bianco, Roberto; De Angelis, Carmine; Veneziani, Bianca Maria | |
| The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance | 1-gen-2019 | Nardone, A.; Weir, H.; Delpuech, O.; Brown, H.; De Angelis, C.; Cataldo, M. L.; Fu, X.; Shea, M. J.; Mitchell, T.; Veeraraghavan, J.; Nagi, C.; Pilling, M.; Rimawi, M. F.; Trivedi, M.; Hilsenbeck, S. G.; Chamness, G. C.; Jeselsohn, R.; Osborne, C. K.; Schiff, R. |